September 10, 2025Blood Cancer JournalOpen Access

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Pooled analysis reveals distinct adverse event profiles among bispecific antibodies in multiple myeloma, suggesting important treatment implications.

GPRC5D/FcRH5 bispecific antibodies have lower rates of grade 3/4 hematologic adverse events.
Among 2,374 patients, neutropenia and infections were the most common all-grade adverse events.
Principal component analysis spotlighted clustering patterns of adverse events across different bispecific antibodies.
BCMA bispecific antibodies were linked to lower occurrences of grade 3/4 cytokine release syndrome.

Golmohammadi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Pooled analysis reveals distinct adverse event profiles among bispecific antibodies in multiple myeloma, suggesting important treatment implications.